Amoéba

Capital/Financing Update • Mar 29, 2023

Amoéba obtains €5.9 million in funding from BPI France as part of France 2030 program

Chassieu (France), March 29th, 2023 – 17:45 – AMOÉBA (FR0011051598 – ALMIB), an industrial biotech in pre-commercialization* specializing in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water, announces the support of BPI France in the framework of the national financing plan "France 2030".

Presented in October 2021, the "France 2030" financing plan aims to provide answers to the major challenges of our time, while raising France to the rank of leader in its industry through three levers: reindustrialising France, investing massively in innovative technologies and supporting the ecological transition.

As a result of its application to the « Résilience et Capacité Agroalimentaire » appeal, Amoéba has officially been nominated as the laureate of the France 2030 project. After examining the application, BPI France recognised the quality and interest of Amoéba's investments, as it is a key player in the agro-ecological transition, and announced a support of €5,917,676 in the form of a €3,550,606 subsidy and a €2,367,070 recoverable advance. At this stage, the company is still pending the terms and timing of the payment of these amounts.

This financing will enable the company to further its industrial project, in particular the creation of its eco-responsible plant, located in the new business park "Hauts Banquets" in Cavaillon, dedicated to naturalness. In addition to the environmental nature of the project, Amoéba's industrialisation meets the innovation criteria of France 2030, with 4.0 facilities and the use of artificial intelligence solutions.

As a reminder, in order to finance its future production site and pursue its operational and research activities over the next three years, the company estimates its total financial expenditure at 45 million euros. Amoéba is currently pursuing its research for the required financing(s).

By industrializing the production of biocontrol solutions in France, Amoéba is committed to putting all its efforts into biological, autonomous and safe agriculture, and to meeting the European objectives of a 50% reduction in the use of pesticides in Europe by 2030, a 25% of cultures treated in Organic Agriculture in Europe by 2030 and the securing of food inputs in Europe.

NEXT APPOINTMENT March 30th, 2023: 2022 Annual results

This project was supported by France 2030

About AMOÉBA :

Amoéba's ambition is to become a major player in the treatment of microbiological risk in the water, plant protection and health sectors. Based on the natural properties of the amoeba Willaertia magna C2c Maky, our biological solution is a viable alternative to the chemical products widely used in the industry today. Amoeba is currently focused on the closed system industrial cooling tower market in the United States estimated at €200 million (1) and on the global biocontrol market for plant protection estimated at €1.6 billion (2), out of a global market for chemical fungicides estimated at €21 billion (3). In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million (4) in the United States. The commercialization of the associated healthcare, biocides and phytosanitary products is subject to local regulatory approvals. *At the end of 2022, Amoeba obtained approval of its active substance for biocidal use in closed cooling system and for biocontrol use in the United States. The substance has also been recommended for biocontrol use in Europe by the Austrian authority in the same year. The company is currently in a precommercialization phase for biocidal and plant protection applications and is expected to market its products by 2025. Founded in 2010 and based in Chassieu (Lyon, France), Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit www.amoeba-nature.com.

(1): Amoéba data

(2): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK (3): Amoeba data (4): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

Contacts :

Amoéba Valérie FILIATRE Deputy General Manager +33 4 26 69 16 00 v.filiatre@amoeba-nature.com Calyptus Investor & Press Relations Nicolas HELIN / Mathieu CALLEUX +33 1 53 65 37 90 /91 amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of AMOEBA to be materially different from such forwardlooking statements.